Strategic Acquisitions LICORbio’s recent acquisition of Serva Electrophoresis expands its electrophoresis reagents, consumables, and workflow instrumentation capabilities, creating cross-sell opportunities across imaging, analysis software, and bundled lab solutions.

Growth and Scale With a revenue range of 100M to 250M and a mid‑sized headcount, LICORbio sits in a growth phase that benefits from enterprise-grade partnerships, channel programs, and larger procurement contracts typical of mid‑market scientific suppliers.

Imaging Leader The firm emphasizes state‑of‑the‑art imaging solutions paired with reagents and software, signaling potential upsell to labs seeking integrated imaging workflows, quantitative analysis, and reliable data outputs across research areas.

Global Collaboration The cross‑border press release and presence in Lincoln and Heidelberg indicate a multinational footprint, suggesting opportunities to target regional R&D teams, distributors, and life sciences networks in Europe and North America.

Evidence‑Driven Value With extensive peer‑review citations and a reputation for speed, accuracy, and consistency, there is a strong case to position LICORbio’s suite as a risk‑reduction buy for labs needing dependable, reproducible results and robust support.